View Older Stories View More Recent Stories

Mar 3, 2022 08:00AM TG Therapeutics (TGTX) Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ
Mar 3, 2022 08:00AM TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL
Mar 1, 2022 07:31AM TG Therapeutics (TGTX) Provides Business Update, Reports Q4
Mar 1, 2022 07:30AM TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
Feb 25, 2022 07:33AM TG Therapeutics (TGTX) Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis
Feb 25, 2022 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple
Feb 24, 2022 07:30AM TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update
Feb 15, 2022 07:31AM TG Therapeutics (TGTX) to Present Data from ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis
Feb 15, 2022 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Mu
Jan 24, 2022 07:30AM TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference
Jan 5, 2022 07:30AM TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Jan 4, 2022 07:30AM TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million
Dec 14, 2021 07:33AM TG Therapeutics (TGTX) Announces Data from the UNITY-CLL Phase 3 Trial Presented at ASH
Dec 14, 2021 07:30AM TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
Dec 14, 2021 07:15AM TG Therapeutics (TGTX) Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of MS
Dec 14, 2021 07:15AM TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
Dec 13, 2021 07:30AM TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting
Dec 10, 2021 07:30AM TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting
Nov 30, 2021 07:33AM TG Therapeutics (TGTX) Issues Regulatory Update
Nov 30, 2021 07:30AM TG Therapeutics Provides Regulatory Update
Nov 15, 2021 07:30AM TG Therapeutics to Participate in the Jefferies London Healthcare Conference
Nov 9, 2021 07:30AM TG Therapeutics to Participate in the B. Riley Securities Fall 2021 Growth Biotech Best Ideas Virtual Series
Nov 4, 2021 09:34AM TG Therapeutics Highlights Data Selected for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
Nov 4, 2021 07:00AM TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
Nov 1, 2021 07:30AM TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business Update
Oct 14, 2021 10:46AM TG Therapeutics (TGTX) Announces Data for Ublituximab in MS Presented at ECTRIMS
Oct 14, 2021 10:45AM TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Sep 30, 2021 07:31AM TG Therapeutics (TGTX) Submits BLA to FDA for Ublituximab as Treatment for Patients with Relapsing Forms of Multiple Sclerosis
Sep 30, 2021 07:30AM TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
Sep 29, 2021 07:32AM TG Therapeutics (TGTX) to Present Data from ULTIMATE I & II Phase 3 Trials of Ublituximab in MS at ECTRIMS
Sep 29, 2021 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment a
Sep 23, 2021 08:00AM TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances
Sep 23, 2021 07:30AM TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Sep 20, 2021 07:36AM TG Therapeutics (TGTX) Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia
Sep 20, 2021 07:30AM TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Sep 13, 2021 09:21AM TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Sep 9, 2021 09:00AM TG Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 30, 2021 07:30AM TG Therapeutics Announces Data Presentations at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Aug 2, 2021 07:00AM TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
Jul 28, 2021 07:30AM TG Therapeutics to Host Conference Call on Second Quarter 2021 Financial Results and Business Update
Jul 9, 2021 07:30AM TG Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference
Jun 29, 2021 07:30AM TG Therapeutics Mourns the Loss of Board Member, William J. Kennedy, PhD
Jun 18, 2021 02:00PM TG Therapeutics (TGTX) Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at EAN
Jun 18, 2021 02:00PM TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology
Jun 18, 2021 07:35AM TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma
Jun 11, 2021 07:02AM TG Therapeutics (TGTX) Highlights Data from Phase 1 Study Evaluating TG-1701 as Monotherapy & as Triple Combination w/ Ublituximab & UKONIQ
Jun 11, 2021 07:00AM TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Co
Jun 9, 2021 07:00AM TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma
Jun 4, 2021 09:08AM TG Therapeutics (TGTX) Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ
Jun 4, 2021 09:00AM TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annu
View More Recent Stories View Older Stories